Benzodiazepines (BZO) Rapid Test Device

Benzodiazepines (BZO) Rapid Test Device by LARKSOIS Pharma is a professional urine-based rapid test designed for qualitative screening of benzodiazepines in human urine specimens. With a 300 ng/mL cut-off, this BZO rapid test device supports hospitals, diagnostic laboratories, rehabilitation centers, occupational health programs, forensic screening settings, and institutional drug monitoring workflows. Benzodiazepines are central nervous system depressant medicines used in controlled medical settings for conditions such as anxiety, insomnia, seizures, muscle spasms, and procedural sedation, but they are also regulated due to misuse, dependence, and safety risks.

Introduction

The Benzodiazepines (BZO) Rapid Test Device is a professional diagnostic product under the Drug of Abuse category. It is designed to detect benzodiazepines in urine at a 300 ng/mL cut-off using a rapid screening format.
Benzodiazepines are also called benzos and are a class of medicines that slow activity in the brain and nervous system. They may be prescribed in controlled medical settings for selected conditions, but they are regulated because of misuse, dependence, and safety risks.
The BZO rapid test urine format helps healthcare professionals, laboratories, and institutional screening programs obtain fast preliminary screening information. Results should always be interpreted by trained professionals and confirmed where required.

What Are Benzodiazepines

Benzodiazepines, abbreviated as BZO in drug testing, are a group of central nervous system depressant medicines. They act on nervous system pathways to produce calming, sedative, muscle-relaxing, and seizure-control effects in approved medical use. Common benzodiazepines include alprazolam, diazepam, lorazepam, clonazepam, temazepam, midazolam, chlordiazepoxide, oxazepam, triazolam, and clobazam.

Intended Use

The Benzodiazepines (BZO) Rapid Test Device is used for preliminary qualitative screening of benzodiazepines in urine. It is designed to support fast screening workflows where healthcare professionals or trained laboratory users need an initial result.

Applications

Drug of abuse screening programs
Clinical toxicology laboratories
Rehabilitation and recovery centers
Occupational health screening
Emergency department screening support
Institutional drug monitoring workflows
Forensic and compliance screening support
Urine-based preliminary benzodiazepine detection

Why Testing Matters

Benzodiazepines can be prescribed legally, but they are controlled in many countries because of safety and misuse risks.
Because benzodiazepines may cause drowsiness, impaired coordination, and slowed nervous system activity, professional screening can be important in clinical toxicology, safety-sensitive workplace programs, rehabilitation monitoring, and compliance-based testing.
The Benzodiazepines (BZO) Rapid Test Device supports responsible screening and reporting systems in controlled professional environments.

Method

The Benzodiazepines (BZO) Rapid Test Device uses a rapid urine screening format and is designed to detect benzodiazepines at a 300 ng/mL cut-off. Urine is commonly used in toxicology screening because it is practical, non-invasive, and suitable for drug-class screening workflows.

Benefits

Urine-based rapid screening format
300 ng/mL benzodiazepine cut-off
Designed for BZO drug screening
Suitable for professional diagnostic use
Supports fast preliminary results
Useful for toxicology and compliance workflows
Applicable for laboratories, clinics, and institutions
Supports international drug screening requirements
Helps standardize urine drug monitoring programs

Specimen

The Benzodiazepines (BZO) Rapid Test Device is designed for urine specimens. Urine is widely used in drug screening because it is practical for detecting drug exposure in professional screening workflows.

Guidance

Use urine specimens only
Use clean sample collection procedures
Follow the product insert carefully
Treat all urine samples as potentially biohazardous
Interpret results within the stated reading window
Use confirmatory testing where required by clinical, legal, workplace, or institutional policy

Note

Rapid screening results should be interpreted with caution. Positive or unexpected results may require confirmation using validated laboratory methods such as GC-MS or LC-MS/MS.

Cut Off

The Benzodiazepines (BZO) Rapid Test Device by LARKSOIS Pharma has a stated cut-off of 300 ng/mL. This means the device is designed to screen for benzodiazepines in urine at or above the validated threshold. LARKSOIS Pharma should mention the exact cut-off and performance details according to the final product insert, technical file, and regulatory documentation.

Procedure

Steps

Bring the test device and urine specimen to the recommended testing condition
Open the sealed pouch only when ready to test
Collect urine using a clean sample collection procedure
Apply the urine specimen according to the product insert
Wait for the test reaction to complete within the instructed time
Read the result within the approved interpretation window
Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Benzodiazepines (BZO) Rapid Test Device.

Result Interpretation

Positive

A positive result suggests that benzodiazepines may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary unless confirmed by an appropriate laboratory method.

Negative

A negative result suggests that benzodiazepines were not detected or were below the test cut-off at the time of testing. A negative result does not replace clinical or professional judgment.

Invalid

If the control indicator does not appear, the result is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Storage

Instructions

Store according to the product label and package insert
Protect from direct sunlight, moisture, high temperature, and contamination
Do not use expired test devices
Do not use damaged or opened pouches
Keep sealed until use
Interpret results within the stated reading window
Treat all urine samples as potentially biohazardous
Dispose of used materials according to laboratory safety rules

Precautions

Instructions

For professional in vitro diagnostic use only
Not intended for home use
Not intended to diagnose substance use disorder
Not intended to diagnose overdose or intoxication
Positive results are preliminary unless confirmed
Negative results do not replace clinical judgment
Confirmatory testing is recommended when results affect medical, legal, workplace, or institutional decisions
Benzodiazepine legality and prescription rules vary by country
Follow local clinical, workplace, forensic, and regulatory guidelines
Benzodiazepines can be habit-forming and may cause dangerous effects when misused or combined with alcohol, opioids, or other sedating substances

Why Choose

LARKSOIS Pharma focuses on reliable diagnostic solutions for global healthcare providers, laboratories, distributors, and institutional screening programs. The Benzodiazepines (BZO) Rapid Test Device is developed for professional environments where speed, clarity, and dependable screening support are important.

Advantages

Urine-based rapid screening format
300 ng/mL benzodiazepine cut-off
Designed for BZO drug screening
Suitable for professional diagnostic use
Supports fast preliminary results
Useful for toxicology and compliance workflows
Applicable for laboratories, clinics, and institutions
Supports international drug screening requirements
Helps standardize urine drug monitoring programs

Frequently Asked Questions

What does BZO mean in drugs?+

BZO usually means benzodiazepines in drug testing. It is a short code used on urine drug screening panels to indicate benzodiazepine-class detection. A positive BZO result is usually considered preliminary until confirmed by a validated laboratory method.

What are 6 benzodiazepine drugs?+

Six common benzodiazepine drugs include alprazolam, diazepam, lorazepam, clonazepam, temazepam, and midazolam. These medicines may have different clinical uses, duration of action, and safety considerations, so they should only be used under medical supervision.

What is an example of a BZO drug?+

An example of a BZO drug is diazepam, commonly known by the brand name Valium. Other examples include alprazolam, lorazepam, clonazepam, temazepam, and midazolam. These drugs belong to the benzodiazepine medicine class.

What drugs classify as BZO?+

BZO-class drugs include benzodiazepines such as alprazolam, diazepam, lorazepam, clonazepam, chlordiazepoxide, oxazepam, temazepam, triazolam, and midazolam. In urine screening, BZO testing usually detects the drug class or related metabolites.

What are the top 5 strongest benzodiazepines?+

Benzodiazepine strength is not safely ranked for general use because potency depends on dose, formulation, duration, patient response, and clinical purpose. Some benzodiazepines are considered higher-potency in medical comparisons, but interpretation should be handled only by qualified healthcare professionals.

↑